Smooth Spinoff Execution

Johnson & Johnson moves ahead with a tax-efficient separation of its orthopedics business, likely centered on DePuy Synthes, while keeping its higher-growth pharmaceuticals and medtech assets together. The raised 2026 profit guide gives management credibility that the company can absorb dis-synergies and still protect margins.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.